The use of erythropoietin to treat anaemia in end-stage renal disease.
Recombinant human erythropoietin (r-HuEPO) has greatly improved the lives of renal patients with anaemia. Nurses who administer r-HuEPO should be aware of its side-effects. Studies are still needed to elicit the most efficient route of administration of r-HuEPO.
Ellis
P
P
Ellis
J A
JA
D000740:Anemia / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*
D004921:Erythropoietin